Insulet Corporation PODD
At closeNov 4, 2026, 4:01 AM EST
Pre-market · Nov 4, 4:01 AM ET
- YTD
- -45.52%
- 1 year
- -51.42%
- Market cap
- 10.74B
- Revenue (ttm)
- 3.05B
- Profit margin
- 12.29%
- EPS (ttm)
- 5.34
- Shares out
- 69.35M
- P/E ratio
- 29.00
- Forward P/E
- 20.05
- YTD return
- -45.52%
- 1-year return
- -51.42%
- Volume
- 1.61M
- Avg volume
- 1.70M
- Open
- 152.08
- Previous close
- 153.61
- Day's range
- 151.23 – 156.98
- 52-week range
- 126.40 – 354.88
- Beta
- 1.05
- Analysts
- Buy
- Price target
- 167.17 (+8.0%)
- Earnings date
- Nov 4, 2026
5D +6.34 (+4.26%)
Key statistics
- Enterprise value
- 11.13B
- PEG ratio
- 1.21
- Price / sales
- 3.52
- Price / book
- 7.55
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 23.50%
- Free cash flow
- 236.90M
- Total cash
- 534.90M
- Total debt
- 1.02B
- Return on equity
- 26.02%
- Short % of float
- 9.16%
- 50-day average
- 141.02
- 200-day average
- 178.13
Analyst view
Consensus: buy
- Target (low)
- 143.00
- Target (mean)
- 167.17
- Target (high)
- 215.00
- Strong buy4
- Buy11
- Hold11
- Sell0
- Strong sell0
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate 1.59.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | 1.59 | — | — | — |
| Aug 5, 2026 | Jun 30, 2026 | 1.47 | 1.66 | +0.19 | +12.93% |
| May 6, 2026 | Mar 31, 2026 | 1.19 | 1.42 | +0.23 | +19.33% |
| Feb 18, 2026 | Dec 31, 2025 | 1.47 | 1.55 | +0.08 | +5.44% |
| Nov 6, 2025 | Sep 30, 2025 | 1.14 | 1.24 | +0.10 | +8.77% |
| Aug 7, 2025 | Jun 30, 2025 | 0.92 | 1.17 | +0.25 | +27.17% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 12, 2026 | Jefferies | main | Buy | Buy |
| Oct 7, 2026 | Barclays | init | — | Equal-Weight |
| Aug 6, 2026 | Canaccord Genuity | main | Buy | Buy |
| Aug 6, 2026 | Leerink Partners | down | Outperform | Market Perform |
| Aug 6, 2026 | TD Cowen | main | Hold | Hold |
| Aug 6, 2026 | UBS | main | Neutral | Neutral |
About Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- insulet.com
News
Insulet to Participate in the 2026 Jefferies Global Healthcare Conference in London 
Insulet Corporation $PODD Stock: International Assets Investment Management LLC Boosts Stake 
Insulet (PODD) Reports Next Week: Wall Street Expects Earnings Growth 
Jefferies Maintains Buy on Insulet, Lowers Price Target to $190 
Insulet Reports Q2 2026 Results: Full Earnings Call Transcript 
Barclays Initiates Coverage On Insulet with Equal-Weight Rating, Announces Price Target of $150 
York Space Systems, Inc. (YSS) 
Swarmer, Inc (SWMR) Latest Stock News & Headlines - Yahoo Finance - Insulet Corporation
- Insulet to Participate in the 2026 Jefferies Global Healthcare Conference in London
Your note
Sign in to keep a note on PODD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BENJAMIN ERIC | Chief Operating Officer | Stock Award(Grant) | Feb 23, 2026 | 24,512 |
| CHADWICK ANA MARIA | Chief Financial Officer | Stock Award(Grant) | Feb 24, 2025 | 16,028 |
| FIELD MARK N | Chief Technology Officer | Stock Award(Grant) | Feb 24, 2025 | 13,915 |
| HOLLINGSHEAD JAMES R | Chief Executive Officer | Stock Award(Grant) | Feb 24, 2025 | 68,068 |
| HOPFIELD JESSICA | Director | Stock Award(Grant) | May 19, 2026 | 29,355 |
| KAPPLES JOHN W. | General Counsel | Stock Award(Grant) | Feb 23, 2026 | 28,119 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.65% | 6,690,192 | 1.04B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.52% | 4,525,333 | 700.79M | Jun 29, 2026 |
| State Street Corporation | 4.61% | 3,197,555 | 495.17M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.44% | 3,075,932 | 476.34M | Jun 29, 2026 |
| AQR Capital Management, LLC | 3.54% | 2,455,135 | 380.20M | Jun 29, 2026 |
| BAILLIE GIFFORD & CO | 2.94% | 2,042,313 | 316.27M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.17% | 2,199,429 | 340.60M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.59% | 1,792,909 | 277.65M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.29% | 1,589,038 | 246.08M | Jun 29, 2026 |
| Invesco Exchange-Traded Fund Trust-Invesco S&P 500 Equal Weight ETF | 2.05% | 1,418,299 | 219.64M | Sep 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 925,214 | 143.28M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.32% | 916,226 | 141.89M | Jun 29, 2026 |